Clinical Trial Update: MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two doses of fingolimod to Copaxone in relapsing-remitting multiple sclerosis was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• COPAXONE (GLATIRAMER ACETATE)
• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Status: TERMINATED | Results posted: 2019-05-28